Literature DB >> 27787286

Haemorrhage at caesarean section: a framework for prevention and research.

Jennifer E Jardine1, Penny Law, Matthew Hogg, Deirdre Murphy, Khalid S Khan.   

Abstract

PURPOSE OF REVIEW: Caesarean section rates are increasing across the world. Postpartum haemorrhage is a major cause of morbidity and mortality; major haemorrhage is more common after caesarean delivery. There is a wide range of practice in the prevention and treatment of postpartum haemorrhage at caesarean section. The aim of this review is to summarize current opinion in the management of postpartum haemorrhage at caesarean section. RECENT
FINDINGS: Recent large randomized controlled trials have shown a possible effect from the routine use of tranexamic acid and ergometrine. Small randomized controlled trials have shown a possible benefit from using carbetocin.
SUMMARY: The impact of postpartum haemorrhage can be reduced by antenatal correction of anaemia. Intraoperative medical management consists of oxytocinon, additional oxytocics +/- tranexamic acid, with at present limited evidence as to the order in which these should be considered. Trials of routine use of cell salvage and tranexamic acid are currently underway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27787286     DOI: 10.1097/GCO.0000000000000328

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  2 in total

1.  Management of a severe peripartum hemorrhage following cesarean section in a dog.

Authors:  Graeme M Doodnaught; Elizabeth O'Toole; Daniel S J Pang
Journal:  Can Vet J       Date:  2020-06       Impact factor: 1.008

2.  Cell salvage and donor blood transfusion during cesarean section: A pragmatic, multicentre randomised controlled trial (SALVO).

Authors:  Khalid S Khan; Philip A S Moore; Matthew J Wilson; Richard Hooper; Shubha Allard; Ian Wrench; Lee Beresford; Tracy E Roberts; Carol McLoughlin; James Geoghegan; Jane P Daniels; Sue Catling; Vicki A Clark; Paul Ayuk; Stephen Robson; Fang Gao-Smith; Matthew Hogg; Doris Lanz; Julie Dodds
Journal:  PLoS Med       Date:  2017-12-19       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.